You are here

Nitric Oxide Microfluidic Sensor

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI112064-01
Agency Tracking Number: R41AI112064
Amount: $600,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-124
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-07-01
Award End Date (Contract End Date): 2016-06-30
Small Business Information
2 Davis Drive
Durham, NC 27709-0003
United States
DUNS: 829409395
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 MARK SCHOENFISCH
 (919) 843-8714
 schoenfisch@unc.edu
Business Contact
 MARK SCHOENFISCH
Phone: (919) 843-8714
Email: mark.schoenfisch@clinicalsensors.com
Research Institution
 UNIV OF NORTH CAROLINA CHAPEL HILL
 
CHAPEL HILL, NC 27599-0001
United States

 Nonprofit college or university
Abstract

DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and intervention are critical to improve patient outcomes Unfortunately current methods of diagnosing sepsis rely on the detection of symptoms e g fever and irregular heart rate that only become evident after the infection has progressed to dangerous levels advanced sepsis The goals of this project are to manufacture prototype miniaturized microfluidic sensors for the measurement of NO levels in drawn blood and determine the potential clinical utility of NO determination in preclinical monomicrobial models of pulmonary sepsis Using indirect analysis methods literature studies have found significant elevations andgt x basal in blood nitric oxide due to sepsis However the lack of a rapid and direct sensor for NO has frustrated the translation of these findings to the clinic Initial studie in a porcine model of polymicrobial sepsis have shown that this microfluidic NO sensor can represents a new paradigm for diagnosing early sepsis and saving lives This finding is supported by in vitro studies showing that macrophages release NO in response to bacteria with increasing magnitude according to bacteria load Through the proposed studies we will develop a novel miniaturized NO sensing platform to enable the rapid measurement of this biomarker in small aliquots of blood After meeting specific analytical performance requirements for this device sensitivity and selectivity for NO linear response range reproducibility etc we will determine the predictive value of NO measurement in established preclinical models of pulmonary sepsis Most in vivo studies of NO in sepsis have been performed in polymicrobial models such as cecal ligation and puncture CLP While this model faithfully recapitulates ruptured appendicitis the microbiological milieu is more complex than most hospital acquired infections i e most catheter related infections and cases of hospital acquired pneumonia have a single etiologic agent Both clinical pneumonia and the preclinical murine models of pneumonia share common immunoinflammatory elements and in contrast to CLP are highly reproducible and titratable These models will allow testing of several clinically significant parameters including differentiating the blood nitric oxide response in Gram positive and Gram negative infections determining whether the in vivo nitric oxide response is proportional to microbial burden and screening commonly used therapeutic modalities for example pain management and antibiotics to assess their affects on the blood nitric oxide response to infection These studies will establish key parameters for the evaluation of the blood nitric oxide sensor in clinical subjects PUBLIC HEALTH RELEVANCE Sepsis is the leading cause of death in non cardiac Intensive Care Units ICUs and the th leading cause of death in the U S overall Prompt detection of sepsis and intervention are critical to saving lives of the critically ill The objective of this poject is to develop a lab on a chip device that allows for rapid detection of nitric oxide in drawn blood
to facilitate early diagnosis reduce hospital costs and save lives

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government